"Ribonucleotides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nucleotides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)
| Descriptor ID |
D012265
|
| MeSH Number(s) |
D13.695.827
|
| Concept/Terms |
Ribonucleotides- Ribonucleotides
- Ribonucleoside Phosphates
- Phosphates, Ribonucleoside
|
Below are MeSH descriptors whose meaning is more general than "Ribonucleotides".
Below are MeSH descriptors whose meaning is more specific than "Ribonucleotides".
This graph shows the total number of publications written about "Ribonucleotides" by people in this website by year, and whether "Ribonucleotides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribonucleotides" by people in Profiles.
-
Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model. Immunology. 2018 07; 154(3):434-451.
-
Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis. J Pharmacol Exp Ther. 2010 Jun; 333(3):717-25.
-
Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol. 2008 Nov; 22(11):2531-43.
-
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer. 2007 Jul 10; 6:46.
-
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol. 2006 Sep; 169(3):1012-25.
-
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction. J Neurosci Res. 2006 Aug 15; 84(3):614-25.
-
The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol Metab. 2006 Sep; 91(9):3592-7.
-
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 2005 Nov 25; 280(47):39582-93.
-
5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol. 2005 Jul 01; 175(1):566-74.
-
Attenuation of ischemia-reperfusion injury in a canine model of autologous renal transplantation. Transplantation. 2004 Sep 15; 78(5):654-9.